FLUARIXTETRA, quadrivalent seasonal influenza vaccine
INFECTIOUS DISEASE - New indication
Opinions on drugs -
Posted on
Dec 18 2018
Reason for request
Extension of indication
» FLUARIXTETRA now has MA for the prevention of seasonal influenza in infants and children, aged from 6 to 35 months.
» In this population, its efficacy and safety profile is comparable overall to that of trivalent influenza vaccines.
» This vaccine targets populations at a risk of severe forms of influenza.
Clinical Benefit
Substantial |
- |
Clinical Added Value
no clinical added value |
- |
Therapeutic use
- |